Draft:SDMA

SDMA (Benzoxathiol-6-yl-N-methyl-propan-2-amine) is a substituted amphetamine derivative with empathogenic effects, which acts as analogue of MDMA with a supposed shorter half-life. SDMA, along with its corresponding nor-compound SDA, are potential candidates for treatment-resistant depression and post-traumatic stress disorder. New SDMA prodrugs are in the development phase at MiHKAL GmbH in Switzerland.